Scilex Holding Company (SCLXW) stock surged +33.22%, trading at $0.16 on NASDAQ, up from the previous close of $0.12. The stock opened at $0.14, fluctuating between $0.14 and $0.16 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 11, 2026 | 0.12 | 0.17 | 0.12 | 0.12 | 9.74K |
| May 08, 2026 | 0.18 | 0.19 | 0.15 | 0.15 | 6.91K |
| May 07, 2026 | 0.20 | 0.20 | 0.18 | 0.18 | 4.14K |
| May 06, 2026 | 0.18 | 0.20 | 0.18 | 0.20 | 2.41K |
| May 05, 2026 | 0.18 | 0.21 | 0.18 | 0.21 | 4.4K |
| May 04, 2026 | 0.20 | 0.21 | 0.16 | 0.20 | 6.51K |
| Apr 30, 2026 | 0.18 | 0.21 | 0.18 | 0.20 | 7K |
| Apr 29, 2026 | 0.18 | 0.18 | 0.14 | 0.18 | 4.26K |
| Apr 28, 2026 | 0.16 | 0.16 | 0.14 | 0.14 | 1.11K |
| Apr 27, 2026 | 0.16 | 0.16 | 0.16 | 0.16 | 206 |
| Apr 23, 2026 | 0.17 | 0.18 | 0.17 | 0.17 | 495 |
| Apr 22, 2026 | 0.18 | 0.18 | 0.17 | 0.17 | 1.71K |
| Apr 21, 2026 | 0.14 | 0.19 | 0.14 | 0.19 | 47.68K |
| Apr 20, 2026 | 0.13 | 0.13 | 0.11 | 0.13 | 3.69K |
| Apr 17, 2026 | 0.12 | 0.12 | 0.12 | 0.12 | 910 |
| Apr 16, 2026 | 0.08 | 0.12 | 0.08 | 0.12 | 1K |
| Apr 14, 2026 | 0.09 | 0.11 | 0.08 | 0.09 | 4.9K |
| Apr 13, 2026 | 0.08 | 0.10 | 0.07 | 0.07 | 32.14K |
| Apr 10, 2026 | 0.09 | 0.09 | 0.08 | 0.08 | 3.74K |
| Apr 09, 2026 | 0.08 | 0.08 | 0.07 | 0.07 | 5.61K |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Employees | 115 |
| Beta | 1.37 |
| Sales or Revenue | $46.74M |
| 5Y Sales Change% | 1.407% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep